This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Divine Skin Announces New Pain Reliever To Compete With Tylenol, Advil, Aspirin

MIAMI BEACH, Fla., June 13, 2011 /PRNewswire/ -- Today Divine Skin Inc. (DSKX), a developer of personal-care biotechnology, announced plans to release a new oral analgesic intended to compete over the counter with the likes of Tylenol, Advil, and aspirin. The company plans to begin shipping upon final authorization by the Drug Enforcement Administration.

"Since Divine Skin focuses on underserved and niche categories, of course our pain medication will offer patients some benefits that competitors don't. The product will give better pain relief, with a safety profile similar to that of Advil," explained Daniel Khesin, chairman and CEO.

"We certainly don't expect to take significant market share away from the huge players, since consumers have been taking Tylenol and Advil for generations. Instead, we will target an audience that appreciates more advanced biotechnology. If we win just one tenth of one percent of the market — which we will — then we'll be happy," he said.

In the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, antiarthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4 billion in 2009, according to an August 2010 report published by the US Census Bureau.

Each patient responds differently to each type of pain and pain reliever. A few years ago, Khesin himself endured a grueling experience with chronic pain after suffering a catastrophic spinal cord injury, which put him in a wheelchair for months. During his recovery, he tried nearly all of the pain relievers then available, including some strong narcotics.

That ordeal, combined with his expertise in business development and the commercialization of new biotechnologies, resulted in what he believed might become a unique over-the-counter medication. Laboratory research showed promise for the new formula, and subsequent clinical studies confirmed the drug's effectiveness.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASDAQ 4,776.5080 -51.8170 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs